semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Obstructive Pulmonary Diseases Restrictive Lung Disease Cough Dyspnea All patients who have undergone pulmonary function testing at the Singapore General Hospital pulmonary function laboratory
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Bronchial Asthma Food Allergy Children Physician diagnosed asthma (12% reversibility on spirometry test or positive response to provocholine® provocation test) Mild to moderate asthmatic children. Asthmatic children with pre-budesonide FEV1/FVC ≥ 80% will be included At least one food allergy confirmed by specific IgE level or skin prick test positivity and a relevant clinical history or open challenge test with food Aged between 6-18 years old Acceptance of involvement in the study and signed informed consent (Both patients and one of the parents)  Who does not sign the informed consent Severe asthmatic children Any lung disease except asthma (i.e. cystic fibrosis, bronchiectasia, primary ciliary dyskinesia) Any systemic disease except allergic rhinitis and atopic dermatitis Follow-up in intensive care unit or intubation for asthma exacerbation within one year Attendance to emergency room or hospital admission within 3 months for asthma exacerbation Systemic steroid usage within 3 months Upper airway infection within one month Psychiatric or psychosocial problems Poor compliance to asthma treatment protocol
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Evaluation of Video Discharge Instructions in Improving Understanding caregivers of pediatric patients age 29 days to 18 years old diagnosed with wheezing or asthma exacerbation, fever, or vomiting and/or diarrhea  Caregivers of patients who were critical in the ED Admitted to the hospital, or given an alternate diagnosis prior to discharge were excluded from the study Also, non-English speaking caregivers were excluded
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-85.0,  Asthma Literacy: The subject must be able to read and comprehend English. Consent: The subject must have the ability to give informed consent. Type of subject: The subject must be seen in the outpatient setting at one of the clinics staffed by faculty members of the Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida College of Medicine Asthma: The subject must have a history of physician diagnosed asthma for at least 1 year and must have a current exacerbation of asthma requiring oral glucocorticosteroids. Asthma exacerbation is defined below. Asthma exacerbation (relapse or de novo) is defined as either: 1. An increase of asthma symptoms (cough, wheeze, chest tightness, and /or shortness of breath) that does not resolve within 2 hours after the use of rescue albuterol or corticosteroids and requires a medical visit or 2. During a scheduled visit, the subject has acute worsening of asthma symptoms and a reduction of >20% in peak flow, which in the opinion of the investigator requires treatment with oral glucocorticosteroids  Females who are pregnant or lactating Any other coexistent lung disease (COPD, interstitial lung disease, allergic bronchopulmonary aspergillosis, TB, sarcoidosis) Any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbates during the study. The list of conditions/diseases that will result in if determined to be clinically significant includes, but is not limited to: uncontrolled hypertension; hematological, hepatic, neurological, thyroid, peptic ulcer, or renal disease; immunologic compromise; current malignancy Past or current use of tobacco (<10 pack year smoking history and no smoking within the last 5 years)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 8.0-50.0,  Cystic Fibrosis Cooperation with spirometry  exacerbation, patients younger than 8 years
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Cough Individuals aged 18-65 years of age with asthma, CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used: 1. asthma: episodic respiratory symptoms occurring in association with variable airflow obstruction (Canadian Asthma Consensus Report definition); 2. CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator); 3. Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 > 16 mg/mL) Individuals aged 18-65 years of age with no history of asthma or chronic cough  an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks inability to perform acceptable spirometry medical contraindications to methacholine challenge testing 1. Severe airflow limitation (FEV1 <50% predicted or <1.0 L); 2. Heart attack or stroke in last 3 months; 3. Uncontrolled hypertension, systolic BP > 200 or diastolic BP > 100; 4. Known aortic aneurysm; 5. Moderate airflow limitation <60% predicted or 1.5) is a relative contraindication; 6. Inability to perform acceptable quality spirometry; 7. Current use of cholinesterase inhibitor medication (for myasthenia gravis); and 8. Pregnant or nursing mothers smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an criterion; medication use will be recorded and examined in the analysis
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Health Communication parents of 0-15 years old children with breathing difficulties caused by LRTI (bronchiolitis, laryngitis or pneumonia) or asthma exacerbation ability to communicate and read Norwegian  parents of children with chronic diseases who have direct access to the acute ward, children with oxygen saturation less than 90 %, or other very sick children who need urgent treatment
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 14.0-17.0,  Asthma Teenagers age 14-17 years inclusive Diagnosis of asthma by a PCP or a specialist at a Partners affiliated hospital/health center Access to computer with internet Active email account Fluency in English (spoken and written) Be on controller medications (such as: inhaled corticosteroids, cromolyn sodium and nedocromil sodium, long-acting beta-agonists (LABAs), and methylxanthines) to control asthma and prevent symptoms from developing Have an active account on Facebook  Disability or co-morbidity precluding regular access to the internet Cognitive impairment
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Able to give written informed consent prior to participation in the study At least 12 years of age at visit 1 and a minimum weight of 45 kilogram (kg) A well-documented requirement for regular treatment with high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids (OCS) Current treatment with an additional controller medication, besides ICS, for at least 3 months or a documented failure in the past 12 months of an additional controller medication for at least 3 successive months Prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma At Visit 1, a pre-bronchodilator FEV1 <80% (for subjects >= 18 years of age), a pre-bronchodilator FEV1 <90% or FEV1:FVC ratio <0.8 (for subjects 12-17 years of age) Previously confirmed history of two or more exacerbations requiring treatment with systemic CS Male or Eligible Female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control) French subjects will be included only if either affiliated to or a beneficiary of a social security category  Current smokers or former smokers with a smoking history of >=10 pack years Presence of a known pre-existing, clinically important lung condition other than asthma A current malignancy or previous history of malignancy in less than 12 months Known, pre-existing, unstable liver disease cirrhosis and known biliary abnormalities Known, pre-existing severe or clinically significant cardiovascular disease known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment Subjects with any eosinophilic diseases QTc(F) ≥450msec or QTc(F) ≥480 msec A history of alcohol/substance abuse Subject with known immunodeficiency
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 13.0-19.0,  Acute Asthma 19 years of age Physician diagnosis of acute asthma at the Emergency Department visit Parent written informed consent Teen written informed assent  Inability to provide informed consent/assent No physician diagnosis of asthma Other co-morbidities that make it impossible for individual to participate
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Asthma Age greater than 6 years and less than 18 years 2. Pre-existing diagnosis of asthma 3. Presenting to the ED with an asthma exacerbation  History of chronic lung or upper airway disease other than asthma 2. History significant, uncorrected congenital heart disease or cardiac arrhythmia 3. History of thyroid disease 4. Impending respiratory failure 5. Allergy to epinephrine 6. Pregnancy 7. PEFR>60% of predicted and clinical asthma score less than 8
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 15.0-21.0,  Gonorrhea Chlamydia Patient in the St. Louis Children's Hospital Emergency Department 21 years old  Evaluation of abuse or sexual assault Activation of the trauma system Level 1 or 2 triage scores (highest severity) Disabilities preventing independent computer use Psychiatric chief complaints Inability to speak English
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Asthma Key A diagnosis of allergic asthma , uncontrolled on current medication History of at least 1 asthma exacerbation during the last 1 year Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted normal value; reversibility following administration of bronchodilator must also be demonstrated (historical positive reversibility or bronchoprovocation result can be used). Key  Baseline IgE levels or body weight outside the omalizumab dosing table Use of tobacco products within the previous 6 months (Social occasional smokers may be included) Recent asthma attack/exacerbation or asthma worsening/ respiratory infection
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthmatic Diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2011 Asthmatic patients already treated with low daily doses of Inhaled Corticosteroids (ICS) (eg budesonide or equivalent lower than 400 mcg/day) or low dose of ICS/Long Acting Beta2 Agonists (LABA) fixed combinations Patients with Forced Expiratory Volume in 1 sec (FEV1) >= 70 % of predicted values Non or ex-smokers Body Mass Index (BMI) >= 18.5 and <= 32 kg/m2  Pregnant or lactating women unless using acceptable methods of contraception Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) History of near fatal asthma Patients with abnormal QTcF at screening Visit Hospitalization due to asthma exacerbation within 4 weeks prior to the screening visit or during the run-in period Lower respiratory tract infection within 4 weeks prior to the screening visit or during the run-in period History of drug addiction or excessive use of alcohol  Diagnosis of restrictive lung disease Patients treated with oral or parenteral corticosteroids in the previous 2 months before the screening visit (3 months for parenteral depot corticosteroids) Significant medical history or any laboratory abnormality indicative of a significant underlying condition
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Asthma Presence of Asthma typical symptoms and signs accompanied by either: a. obstruction in Spirometry, OR b. positive methacholine test 2. Regular use of high dose of inhaled corticosteroids (1000 micrograms of fluticasone per day or equivalent) in addition to a long acting beta agonist (LABA). 3. Lack of asthma control or more exacerbations in the past year exacerbations defined by hospitalization or care in an emergency department or treatment with systemic glucocorticosteroids for exacerbation of asthma symptoms  Presence of another relevant respiratory illness, such as chronic obstructive pulmonary disease (COPD) 2. lack of adherence to medical therapy